Movement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan

Market Focus07-06

On July 6, TransThera Sciences-B rose 6.19% in regular trading, trading at HK$12.56/share, with turnover of HK$136 million. The stock was lifted by a broad biotech sector rally alongside company-specific catalysts including recent clinical milestones and a share buyback plan.

On July 1, the company announced that its global registrational Phase III clinical trial of tinengotinib monotherapy for advanced cholangiocarcinoma completed patient enrollment. The same day, its TT-01488 Phase II clinical trial combining anti-CD20 monoclonal antibody therapy for mantle cell lymphoma received approval from China's NMPA. Additionally, on June 28, the board announced a plan to repurchase up to RMB 100 million of H shares on the open market, bolstering market confidence.

At the sector level, biotech stocks rallied broadly, with Innovent Bio up 7.4%, Remegen up 6.26%, and SKB Bio up 6.41%, reflecting strong industry sentiment that further supported the stock's rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135423515?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135423515","market":"hk","top_or_hot":-1,"title":"Movement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan","media":"Market Focus","content":"<p><p>On July 6, TransThera Sciences-B rose 6.19% in regular trading, trading at HK$12.56/share, with turnover of HK$136 million. The stock was lifted by a broad biotech sector rally alongside company-specific catalysts including recent clinical milestones and a share buyback plan.</p><p>On July 1, the company announced that its global registrational Phase III clinical trial of tinengotinib monotherapy for advanced cholangiocarcinoma completed patient enrollment. The same day, its TT-01488 Phase II clinical trial combining anti-CD20 monoclonal antibody therapy for mantle cell lymphoma received approval from China's NMPA. Additionally, on June 28, the board announced a plan to repurchase up to RMB 100 million of H shares on the open market, bolstering market confidence.</p><p>At the sector level, biotech stocks rallied broadly, with Innovent Bio up 7.4%, Remegen up 6.26%, and SKB Bio up 6.41%, reflecting strong industry sentiment that further supported the stock's rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜TransThera Sciences-B Rises 6.19% in Regular Trading, Biotech Sector Rally Combined with Clinical Milestones and Buyback Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, TransThera Sciences-B rose 6.19% in regular trading, trading at HK$12.56/share, with turnover of HK$136 million. The stock was lifted by a broad biotech sector rally alongside company-specific catalysts including recent clinical milestones and a share buyback plan.</p><p>On July 1, the company announced that its global registrational Phase III clinical trial of tinengotinib monotherapy for advanced cholangiocarcinoma completed patient enrollment. The same day, its TT-01488 Phase II clinical trial combining anti-CD20 monoclonal antibody therapy for mantle cell lymphoma received approval from China's NMPA. Additionally, on June 28, the board announced a plan to repurchase up to RMB 100 million of H shares on the open market, bolstering market confidence.</p><p>At the sector level, biotech stocks rallied broadly, with Innovent Bio up 7.4%, Remegen up 6.26%, and SKB Bio up 6.41%, reflecting strong industry sentiment that further supported the stock's rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1135423515","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135423515","pubTimestamp":1783305047,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, TransThera Sciences-B rose 6.19% in regular trading, trading at HK$12.56/share, with turnover of HK$136 million. The stock was lifted by a broad biotech sector rally alongside...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"动向提示|TransThera Sciences-B常规交易上涨6.19%，生物科技板块涨势叠加临床里程碑和回购计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"On July 6, TransThera Sciences-B rose 6.19% in regular trading, trading at HK$12.56/share, with turnover of HK$136 million. The stock was lifted by a broad biotech sector rally alongside company-specific catalysts including recent clinical milestones and a share buyback plan.On July 1, the company announced that its global registrational Phase III clinical trial of tinengotinib monotherapy for advanced cholangiocarcinoma completed patient enrollment. The same day, its TT-01488 Phase II clinical trial combining anti-CD20 monoclonal antibody therapy for mantle cell lymphoma received approval from China's NMPA. Additionally, on June 28, the board announced a plan to repurchase up to RMB 100 million of H shares on the open market, bolstering market confidence.At the sector level, biotech stocks rallied broadly, with Innovent Bio up 7.4%, Remegen up 6.26%, and SKB Bio up 6.41%, reflecting strong industry sentiment that further supported the stock's rebound.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135423515","isCrawlerRequest":true}